Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

73.34EUR
9:31am EST
Change (% chg)

€0.42 (+0.58%)
Prev Close
€72.92
Open
€72.76
Day's High
€73.52
Day's Low
€72.59
Volume
706,094
Avg. Vol
2,546,124
52-wk High
€80.44
52-wk Low
€62.88

Chart for

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 30.48 33.71
EPS (TTM): 3.70 -- --
ROI: 5.69 14.98 14.48
ROE: 8.50 16.31 15.99

FDA advisory panel split over Sanofi-Lexicon diabetes drug

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

Jan 17 2019

UPDATE 2-FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

Jan 17 2019

FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 Independent experts on an FDA advisory panel were equally split when voting on whether to approve an oral treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

Jan 17 2019

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Jan 07 2019

UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Jan 07 2019

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

PARIS Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

Jan 07 2019

CORRECTED-UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal

PARIS, Jan 7 Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

Jan 07 2019

Drugmakers Sanofi, Regeneron restructure immuno-oncology deal

PARIS, Jan 7 Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million.

Jan 07 2019

Sanofi to invest 80 mln euros in German biotech group BioNTech

FRANKFURT, Jan 4 French drugmaker Sanofi will invest 80 million euros ($90.9 million) in BioNTech and expand its collaboration with the German biotech group, BioNTech said on Friday.

Jan 04 2019

Sanofi's pediatric hexavalent vaccine approved by U.S. FDA

PARIS The U.S. Food and Drug Administration approved Sanofi's new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

Dec 26 2018

Earnings vs. Estimates